Retatrutide's triple agonism adds ~2–4 percentage points over tirzepatide's dual agonism — the smallest gap in the GLP class. Critical caveat: retatrutide's data is Phase 2 only; tirzepatide has full Phase 3 data.
Retatrutide's ~24.2% weight loss comes from a Phase 2 trial (n=338, 48 weeks). Tirzepatide's ~20–22% comes from SURMOUNT-1 Phase 3 (n=2,539, 72 weeks). Phase 2 trials enroll smaller, more selected populations and typically show higher efficacy than Phase 3. The TRIUMPH Phase 3 program is ongoing — retatrutide's final Phase 3 weight loss figure may be lower than 24.2%.
The glucagon receptor component in retatrutide drives energy expenditure through brown adipose tissue thermogenesis and increases fat oxidation — mechanisms that tirzepatide's dual agonism does not access. This is why retatrutide shows greater weight loss despite tirzepatide already being the most effective approved GLP-1 agent. The trade-off is a higher nausea burden (~47–58% vs ~33–45%) and the absence of long-term safety data.
| Timepoint | Retatrutide | Tirzepatide |
|---|---|---|
| Week 4 | ~2–4% | ~2–3% |
| Week 12 | ~7–10% | ~6–8% |
| Week 24 | ~14–17% | ~12–14% |
| Week 36 | ~19–22% | ~16–18% |
| Week 48 | ~24.2% (Phase 2 endpoint) | ~18–20% |
| Week 72 | Phase 3 data pending | ~20–22% (SURMOUNT-1) |
Retatrutide data from Phase 2 (n=338, 48-week primary endpoint). Tirzepatide data from SURMOUNT-1 Phase 3 (n=2,539, 72-week primary endpoint). Direct comparison is cross-trial.
| Parameter | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor mechanism | GLP-1 + GIP + Glucagon (triple) | GLP-1 + GIP (dual agonist) |
| Average weight loss (max dose) | ~24.2% (12 mg, Phase 2) | ~20–22% (15 mg, SURMOUNT-1, Ph3) |
| Average weight loss (mid dose) | ~17.3% (4 mg, Phase 2) | ~17–19% (10 mg, SURMOUNT-1) |
| Data phase | Phase 2 only (TRIUMPH ongoing) | Phase 3 (SURMOUNT program) |
| Trial duration | 48 weeks (Phase 2) | 72 weeks (SURMOUNT-1) |
| FDA approval status | Not approved (est. 2027–2028) | Approved (Mounjaro/Zepbound) |
| Nausea rate (therapeutic dose) | ~47–58% (Phase 2) | 33–45% |
| GI discontinuation rate | Phase 2 data pending Ph3 | ~5–8% |
| Half-life | ~6 days (weekly injection) | ~5 days (weekly injection) |
| Cardiovascular outcome data | No CV outcome data yet | SURPASS-CVOT (ongoing) |
| Long-term safety data | Phase 2 only (limited) | 3+ years real-world data |
| Research-grade availability | Available (Purgo Labs) | Available (Purgo Labs) |
| Comparison | Weight Loss Gap |
|---|---|
| Semaglutide vs Retatrutide | ~15% vs ~24% (~9 pp) |
| Semaglutide vs Tirzepatide | ~15% vs ~22% (~7 pp) |
| Retatrutide vs Tirzepatide | ~24% vs ~22% (~2–4 pp) |
The retatrutide vs tirzepatide gap (~2–4 pp) is the smallest in the GLP class. The semaglutide vs retatrutide gap (~9 pp) is the largest. Notably, the retatrutide vs tirzepatide comparison is the only one where both compounds are not yet in Phase 3 head-to-head data — making it the most uncertain comparison in the matrix.
Purgo Labs supplies research-grade retatrutide and tirzepatide with third-party HPLC + mass spectrometry COAs. Use code HEALTH for 15% off.
Shop Purgo LabsIn available data, yes — retatrutide 12 mg produced ~24.2% weight loss at 48 weeks in Phase 2, compared to tirzepatide 15 mg ~20–22% at 72 weeks in SURMOUNT-1 (Phase 3). However, this comparison has a critical caveat: retatrutide's data is Phase 2 only, while tirzepatide's is Phase 3. Phase 2 trials typically show higher efficacy than Phase 3 in broader populations. The gap may narrow when retatrutide's TRIUMPH Phase 3 results are published (expected 2025–2027).
In current data, retatrutide 12 mg produces approximately 2–4 percentage points more weight loss than tirzepatide 15 mg: ~24.2% vs ~20–22%. For a 100 kg person, this translates to roughly 2–4 kg additional loss with retatrutide. This is the smallest gap in the GLP class — semaglutide vs retatrutide (~15% vs ~24%) shows a much larger 9-point difference. Phase 3 data may narrow or eliminate the retatrutide vs tirzepatide gap.
Retatrutide adds glucagon receptor agonism on top of the GLP-1 + GIP dual agonism shared with tirzepatide. Glucagon receptor activation increases energy expenditure through thermogenesis, promotes fat oxidation (especially hepatic fat), and reduces food intake via central mechanisms. This third receptor mechanism is the primary reason retatrutide shows greater weight loss in Phase 2 data. The trade-off is higher nausea rates (~47–58% vs ~33–45% for tirzepatide) due to glucagon's independent GI effects.
Tirzepatide's ~20–22% weight loss comes from SURMOUNT-1, a Phase 3 trial (n=2,539, 72 weeks). Retatrutide's ~24.2% comes from a Phase 2 trial (n=338, 48 weeks). Phase 2 trials are smaller, shorter, and enroll more homogeneous populations — they typically show higher efficacy than Phase 3 results in broader real-world populations. Retatrutide's TRIUMPH Phase 3 program is ongoing with results expected 2025–2027. The final Phase 3 weight loss figure may be lower than 24.2%.
Retatrutide has worse nausea than tirzepatide based on Phase 2 data. Tirzepatide nausea rates are ~33–45% at therapeutic doses. Retatrutide showed ~47–58% nausea at the 12 mg dose in Phase 2 — approximately 10–15 percentage points higher. The additional glucagon receptor agonism in retatrutide has independent GI effects that add to the nausea burden. Both compounds use slow titration protocols to minimize GI side effects.
No. As of April 2026, retatrutide is not FDA approved. Phase 3 TRIUMPH trials are ongoing with primary completion expected 2025–2026 and NDA submission estimated for 2026–2027. Potential FDA approval is estimated for 2027–2028. Tirzepatide (Mounjaro) was FDA approved for T2D in May 2022 and (Zepbound) for obesity in November 2023.
Yes. Research-grade retatrutide and tirzepatide are available from verified suppliers like Purgo Labs for in vitro and preclinical research purposes. This is distinct from FDA-approved Mounjaro and Zepbound (tirzepatide), which require a prescription. Purgo Labs' research-grade compounds come with third-party COAs from accredited US labs confirming ≥99% purity.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.